Literature DB >> 24023463

Prevalence and significance of electrocardiographic changes and side effect profile of regadenoson compared with adenosine during myocardial perfusion imaging.

Maliha Zahid1, Aaysha Kapila, Cecelia E Eagan, David A Yusko, Edwin D Miller, Cheryl D Missenda.   

Abstract

BACKGROUND: Significance of electrocardiogram (EKG) changes associated with regadenoson as well as side effects compared to adenosine in a real world, unselected population is unknown. METHODS AND
RESULTS: Three hundred ninety six consecutive patients undergoing either adenosine or regadenoson-based single-isotope (Technetium 99c) nuclear images were evaluated. A standard form documenting side effects was filled immediately following administration. The EKGs and nuclear scans were reviewed in a blinded-fashion. Commonest symptoms reported were flushing (64%), chest pain (36%) and dyspnea (36%). Flushing and chest pain were significantly more common with adenosine (73% vs. 57%, P < 0.01 and 53% vs. 47%, P = 0.06) and dyspnea more with regadenoson (40% vs. 31%, P = 0.05). Sixty (29%) patients carried a diagnosis of chronic bronchitis or asthma but only 4 (2 with each) required aminophylline. There was no significant correlation between chest pain induced by either agent or ischemia on nuclear imaging. EKG changes occurred infrequently (16% with regadenoson and 10% with adenosine), and had low sensitivity for detecting ischemia (7% for regadenoson and 11% for adenosine).
CONCLUSIONS: EKG changes with adenosine and regadenoson occur infrequently and have low sensitivity for detecting ischemia. Chest pain is frequently induced by both, and is not predictive of ischemia on nuclear imaging.

Entities:  

Keywords:  Adenosine; Electrocardiographic changes; Regadenoson

Year:  2013        PMID: 24023463      PMCID: PMC3758102          DOI: 10.1016/j.jcdr.2012.10.001

Source DB:  PubMed          Journal:  J Cardiovasc Dis Res        ISSN: 0975-3583


  14 in total

1.  Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging.

Authors:  Robert C Hendel; Timothy M Bateman; Manuel D Cerqueira; Ami E Iskandrian; Jeffrey A Leppo; Brent Blackburn; John J Mahmarian
Journal:  J Am Coll Cardiol       Date:  2005-11-09       Impact factor: 24.094

2.  Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.

Authors:  Zehra Husain; Gurunanthan Palani; Rafael Cabrera; Aarthee S Karthikeyan; Sunitha Dhanalakota; Suba Pathmanathan; Gordon Jacobsen; Karthik Ananthasubramaniam
Journal:  Int J Cardiovasc Imaging       Date:  2011-12-27       Impact factor: 2.357

3.  Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients.

Authors:  João L Cavalcante; Joaquim Barboza; Karthik Ananthasubramaniam
Journal:  J Nucl Cardiol       Date:  2011-05-28       Impact factor: 5.952

4.  Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

Authors:  Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

5.  Angiographic and hemodynamic determinants of myocardial ischemia during adenosine thallium-201 scintigraphy in coronary artery disease.

Authors:  S Nishimura; K T Kimball; J J Mahmarian; M S Verani
Journal:  Circulation       Date:  1993-04       Impact factor: 29.690

6.  Adenosine radionuclide perfusion imaging in the preoperative evaluation of patients undergoing peripheral vascular surgery.

Authors:  E S Marshall; J S Raichlen; S Forman; G P Heyrich; W D Keen; H H Weitz
Journal:  Am J Cardiol       Date:  1995-10-15       Impact factor: 2.778

7.  Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Brian R Leaker; B O'Connor; Trevor T Hansel; Peter J Barnes; Lixen Meng; Vandana S Mathur; Hsiao D Lieu
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

8.  Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial.

Authors:  John J Mahmarian; Manuel D Cerqueira; Ami E Iskandrian; Timothy M Bateman; Gregory S Thomas; Robert C Hendel; Lemuel A Moye; Ann W Olmsted
Journal:  JACC Cardiovasc Imaging       Date:  2009-08

9.  Safety of regadenoson in patients with end-stage renal disease.

Authors:  Wael Aljaroudi; Daniel Hermann; Fadi Hage; Jaekyeong Heo; Ami E Iskandrian
Journal:  Am J Cardiol       Date:  2009-11-18       Impact factor: 2.778

10.  A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.

Authors:  Karthik Ananthasubramaniam; Robert Weiss; Bruce McNutt; Barbara Klauke; Kathleen Feaheny; Stan Bukofzer
Journal:  J Nucl Cardiol       Date:  2012-01-19       Impact factor: 5.952

View more
  5 in total

1.  Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging.

Authors:  Rami Doukky; Adebayo Olusanya; Raj Vashistha; Abhimanyu Saini; Ibtihaj Fughhi; Khaled Mansour; Abiy Nigatu; Kara Confer; Shannon A Sims
Journal:  J Nucl Cardiol       Date:  2015-04-24       Impact factor: 5.952

2.  Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.

Authors:  Efstathia Andrikopoulou; Charity J Morgan; Lizbeth Brice; Navkaranbir S Bajaj; Harish Doppalapudi; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-10-17       Impact factor: 5.952

3.  Impact of pharmacological stress agent on patient motion during rubidium-82 myocardial perfusion PET/CT.

Authors:  Matthew J Memmott; Christine M Tonge; Kimberley J Saint; Parthiban Arumugam
Journal:  J Nucl Cardiol       Date:  2017-01-04       Impact factor: 5.952

4.  Evaluation of the risk factors for ventricular arrhythmias secondary to QT prolongation induced by papaverine injection during coronary flow reserve studies using a 4 Fr angio-catheter.

Authors:  Yoshitaka Okabe; Kanichi Otowa; Yasuhito Mitamura; Hisayoshi Murai; Soichiro Usui; Shuichi Kaneko; Masayuki Takamura
Journal:  Heart Vessels       Date:  2018-04-30       Impact factor: 2.037

5.  Significance of New, Isolated T-wave Inversion in Multiple Electrocardiogram Leads with Regadenoson Injection in Patients with Normal Myocardial Perfusion Imaging: An Observational Report of 5 Consecutive Cases.

Authors:  Robert T Tung
Journal:  Kans J Med       Date:  2019-08-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.